Insys Therapeutics, a once high-flying drug maker, has agreed to pay $225 million to settle criminal and civil investigations into marketing practices of using kickbacks to persuade doctors to prescribe its Subsys painkiller, which contains fentanyl, a powerful and addictive opioid.

As part of the deal, an Insys subsidiary will plead guilty to five counts of mail fraud, while the company will pay a $2 million fine, $28 million in forfeitures, and $195 million to settle charges of violating the federal False Claims Act, which involves defrauding the federal government through sales to health care programs such as Medicare. The company must also sell the painkiller within a year.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy